Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)

Introduction: Mesenchymal epidermal transition and vascular endothelial growth factor pathways are important in mediating non-small cell lung cancer (NSCLC) tumorigenesis and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance. We hypothesized that treatment with caboz...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckamp, Karen L., Frankel, Paul H., Ruel, Nora, Mack, Philip C., Gitlitz, Barbara J., Li, Tianhong, Koczywas, Marianna, Gadgeel, Shirish M., Cristea, Mihaela C., Belani, Chandra P., Newman, Edward M., Gandara, David R., Lara, Primo N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421302/
https://www.ncbi.nlm.nih.gov/pubmed/30915273
http://dx.doi.org/10.3389/fonc.2019.00132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421302/
https://www.ncbi.nlm.nih.gov/pubmed/30915273
http://dx.doi.org/10.3389/fonc.2019.00132

Ejemplares similares